Glenmark Pharma: Rs 9,350-cr Hengrui cancer pact 2026

A licensing deal and a settlement, both in oncology

Glenmark Pharmaceuticals has reported two separate developments tied to its oncology portfolio. Its specialty arm, Glenmark Specialty S.A, announced an exclusive licence agreement with China-based Hengrui Pharma for a lung cancer therapy, Trastuzumab Rezetecan (SHR-A1811). Separately, Glenmark and its US-based unit said they have reached a settlement agreement with Pfizer Inc related to Axitinib Tablets, a kidney cancer treatment.

The announcements matter for different reasons. The Hengrui transaction strengthens Glenmark’s access to a late-stage oncology asset for select markets, including India. The Pfizer settlement addresses a legal pathway for Glenmark’s generic version of Inlyta, Pfizer’s branded Axitinib product.

Key terms of the Hengrui licence for Trastuzumab Rezetecan

Under the out-licensing agreement, Glenmark is liable to make an upfront payment of Rs 154 crore. It may also make milestone payments of up to Rs 9,350 crore, along with corresponding royalties linked to sales of the therapy.

Glenmark described the transaction as an exclusive $1 billion licence agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811). While the total deal value is cited in dollars, the company’s disclosed payment schedule included rupee equivalents for the upfront and milestone amounts.

What markets Glenmark gets, and what it can do there

Glenmark has obtained exclusive rights in select markets, including India, to develop and commercialise the therapy. The company did not list all geographies in the provided details, but it clearly indicated that the rights are limited to certain regions rather than worldwide.

The scope of rights covers development and commercialisation, indicating Glenmark will take responsibility for moving the product through local regulatory steps and building the go-to-market strategy in the covered markets.

What the therapy is approved for, and what else is being explored

Trastuzumab Rezetecan (SHR-A1811) is currently approved for the treatment of HER2-positive cancers, including non-small cell lung cancer (NSCLC). The therapy is also being explored for a breast cancer indication, based on the information provided.

Glenmark also described the therapy as engineered to bind the HER2 (Herceptin) protein. The company said this binding helps inhibit its pairing, aligning with the broader mechanism of HER2-targeted therapies.

The Pfizer settlement over Axitinib tablets

In a separate disclosure, Glenmark Pharmaceuticals said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. Glenmark and its US-based unit signed the settlement pact with Pfizer Inc for Axitinib Tablets in strengths of 1 mg and 5 mg.

Glenmark’s product is the generic version of Pfizer’s Inlyta tablets, used to treat kidney cancer. The update also referenced Pfizer entities PF Prism C.V., PF Prism IMB B.V., and PF Prism C.V. as part of the settlement counterparties.

Regulatory status: earlier USFDA tentative approval

Glenmark noted that it had previously announced tentative approval from the United States Food and Drug Administration (USFDA) for its generic Axitinib tablets (1 mg and 5 mg). The tentative approval was dated November 30, 2020.

The company also described Axitinib as an anti-cancer medication that works by blocking the action of an abnormal protein that signals cancer cells to multiply.

Stock reaction: Glenmark shares trade higher

Following the settlement news, Glenmark’s shares traded higher in early trade. Reports cited the stock up about 1.54% at Rs 417.9 apiece on the BSE, and also about 1.32% higher at around Rs 417.

Additional intraday details showed the scrip moving from a previous close of Rs 411.55, opening at Rs 412.05, and touching an intraday high of Rs 417.70 and low of Rs 412.05. Another quoted trading level was Rs 415.85, up 1.02% over a previous close of Rs 411.65.

Key facts at a glance

Market impact: what investors are likely tracking

From a market perspective, the immediate measurable impact in the provided information is the stock’s move higher on the day of the settlement update, with Glenmark trading near Rs 417-418. The settlement announcement is relevant for investors because it reduces uncertainty around legal disputes tied to the US generics opportunity for Axitinib.

The Hengrui licensing agreement is likely to be tracked through the disclosed payment structure. The upfront payment and the milestone structure (both disclosed in rupees) indicate that a meaningful portion of the economics is linked to future development and commercial progress, with royalties tied to eventual sales.

Analysis: why these two updates matter together

Taken together, the two announcements show Glenmark operating on both sides of oncology value creation. The Hengrui agreement adds a specialty-portfolio asset where Glenmark has exclusive rights in select markets, including India, and a payment schedule tied to execution milestones. At the same time, the Pfizer settlement is consistent with a generics strategy where patent and litigation outcomes can determine market entry for products like Axitinib.

Glenmark also stated it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, alongside internal filings. That context is relevant because the Hengrui licence is explicitly an external partnership, while the Axitinib settlement supports portfolio expansion through generics.

Conclusion

Glenmark’s latest updates combine a large oncology licensing deal for Trastuzumab Rezetecan in select markets, including India, with a US-focused settlement with Pfizer for generic Axitinib tablets. Investors will watch for future disclosures on development and commercial timelines for SHR-A1811 in Glenmark’s territories and any next steps arising from the Axitinib settlement and earlier USFDA tentative approval.